Gene therapeutic approaches to inhibit hepatitis B virus replication

World Journal of Hepatology

Volumn 7, Issue 2, 2015, Pages 150-164

  Gebbing, Maren ^a   Bergmann, Thorsten ^a   Schulz, Eric ^a   Ehrhardt, Anja ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Antisense nucleic acid; Designer nuclease; DNA vaccination; DNAzyme; Dominant negative mutant; External guide sequence; Gene therapy; Hepatitis B virus; Ribozyme; RNA interference

Indexed keywords

EID: 84922474770     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i2.150     Document Type: Review

References (148)

1. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651-693 [PMID: 3039907 DOI: 10.1146/annurev.bi.56.070187.003251]
2. Glebe D, Bremer CM. The molecular virology of hepatitis B virus. Semin Liver Dis 2013; 33: 103-112 [PMID: 23749666 DOI: 10.1055/s-0033-1345717]
3. WHO. Hepatitis B Fact Sheet No. 204. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/
4. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275-284 [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33]
5. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39 Suppl 1: S93-S98 [PMID: 14708685 DOI: 10.1016/s0168-8278(03)00207-1]
6. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-467 [PMID: 18585385 DOI: 10.1053/j.gastro.2008.05.031]
7. Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol 2014; 6: 284-292 [PMID: 24868322 DOI: 10.4254/wjh.v6.i5.284]
8. Jin L, Zeng X, Liu M, Deng Y, He N. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics 2014; 4: 240-255 [PMID: 24505233 DOI: 10.7150/thno.6914]
9. Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods. Curr Pharm Biotechnol 2013; 14: 46-60 [PMID:23437936 DOI: 10.2174/1389201011314010008]
10. Pezzoli D, Kajaste-Rudnitski A, Chiesa R, Candiani G. Lipid-based nanoparticles as nonviral gene delivery vectors. Methods Mol Biol 2013; 1025: 269-279 [PMID: 23918345 DOI: 10.1007/978-1-62703-462-3_21]
11. Demeneix B, Behr JP. Polyethylenimine (PEI). Adv Genet 2005; 53: 217-230 [PMID: 16240995 DOI: 10.1016/S0065-2660(05)53008-6]
12. Davis BR, Brown DB, Prokopishyn NL, Yannariello-Brown J. Micro-injection-mediated hematopoietic stem cell gene therapy. Curr Opin Mol Ther 2000; 2: 412-419 [PMID: 11249771]
13. Johnston SA, Tang DC. Gene gun transfection of animal cells and genetic immunization. Methods Cell Biol 1994; 43 Pt A: 353-365 [PMID: 7823871]
14. Murakami T, Sunada Y. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther 2011; 11: 447-456 [PMID: 22023474 DOI: 10.2174/156652311798 192860]
15. Escoffre JM, Zeghimi A, Novell A, Bouakaz A. In-vivo gene delivery by sonoporation: recent progress and prospects. Curr Gene Ther 2013; 13: 2-14 [PMID: 23157546 DOI: 10.2174/15665231380 4806606]
16. Schwerdt JI, Goya GF, Calatayud MP, Hereñú CB, Reggiani PC, Goya RG. Magnetic field-assisted gene delivery: achievements and therapeutic potential. Curr Gene Ther 2012; 12: 116-126 [PMID:22348552 DOI: 10.2174/156652312800099616]
17. Hodges BL, Scheule RK. Hydrodynamic delivery of DNA. Expert Opin Biol Ther 2003; 3: 911-918 [PMID: 12943450 DOI: 10.1517/14712598.3.6.911]
18. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358 [PMID: 12728277 DOI: 10.1038/nrg1066]
19. Cots D, Bosch A, Chillón M. Helper dependent adenovirus vectors: progress and future prospects. Curr Gene Ther 2013; 13: 370-381 [PMID: 24369061 DOI: 10.2174/156652321305131212125338]
20. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12: 341-355 [PMID: 21499295 DOI: 10.1038/nrg2988]
21. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267 [PMID: 8602510 DOI: 10.1126/science.272.5259.263]
22. Goodarzi G, Gross SC, Tewari A, Watabe K. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J Gen Virol 1990; 71 (Pt 12): 3021-3025 [PMID: 2177093 DOI: 10.1099/0022-1317-71-12-3021]
23. Blum HE, Galun E, von Weizsäcker F, Wands JR. Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. Lancet 1991; 337: 1230 [PMID: 1673773 DOI: 10.1016/0140-6736(91)92907-J]
24. Reinis M, Reinisová M, Korec E, Hlozánek I. Inhibition of hepatitis B virus surface gene expression by antisense oligodeoxynucleotides in a human hepatoma cell line. Folia Biol (Praha) 1993; 39: 262-269 [PMID: 8206172]
25. Zhang YC, Taylor MM, Samson WK, Phillips MI. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs. Methods Mol Med 2005; 106: 11-34 [PMID: 15375310]
26. Offensperger WB, Offensperger S, Walter E, Teubner K, Igloi G, Blum HE, Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993; 12: 1257-1262 [PMID: 8458338]
27. Korba BE, Gerin JL. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Res 1995; 28: 225-242 [PMID: 8629815 DOI: 10.1016/0166-3542(95)0 0050-V]
28. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992; 267: 12436-12439 [PMID: 1618751]
29. Matsukura M, Koike K, Zon G. Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Toxicol Lett 1995; 82-83: 435-438 [PMID:8597090 DOI: 10.1016/0378-4274(95)03574-5]
30. Yao ZQ, Zhou YX, Wang AL, Bai XF, Yang WS. Inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides. J Viral Hepat 1995; 2: 85-89 [PMID:7493302 DOI: 10.1111/j.1365-2893.1995.tb00011.x]
31. Robaczewska M, Narayan R, Seigneres B, Schorr O, Thermet A, Podhajska AJ, Trepo C, Zoulim F, Nielsen PE, Cova L. Sequencespecific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). J Hepatol 2005; 42: 180-187 [PMID:15664242 DOI: 10.1016/j.jhep.2004.10.010]
32. Sun Z, Xiang W, Guo Y, Chen Z, Liu W, Lu D. Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription. Biochem Biophys Res Commun 2011; 409: 430-435 [PMID: 21596023 DOI: 10.1016/j.bbrc.2011.05.016]
33. Walton CM, Wu CH, Wu GY. A ribonuclease H-oligo DNA conjugate that specifically cleaves hepatitis B viral messenger RNA. Bioconjug Chem 2001; 12: 770-775 [PMID: 11562195 DOI: 10.1021/bc010018e]
34. Guang L, Yuan F, Xi M, Zhao C, Liu L, Wen E, Ai Y. Combination and cleavage of HBV DNA fragments by triple helix-forming oligonucleotides modified with manganese porphyrin in vitro. Chin Med J (Engl) 2003; 116: 1248-1252 [PMID: 12935421]
35. Madon J, Blum HE. Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells. Hepatology 1996; 24: 474-481 [PMID: 8781310 DOI: 10.1002/hep.510240302]
36. Nakazono K, Ito Y, Wu CH, Wu GY. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 1996; 23: 1297-1303 [PMID: 8675142 DOI: 10.1002/hep.510230601]
37. Wu J, Gerber MA. The inhibitory effects of antisense RNA on hepatitis B virus surface antigen synthesis. J Gen Virol 1997; 78 (Pt 3): 641-647 [PMID: 9049416]
38. Zhang J, Chen F, Zhong S, Tang K, Shi X, Wang M, Peng J. Anti-HBV effect of targeted antisense RNA against HBV C gene. Zhonghua Ganzangbing Zazhi 2000; 8: 169-170 [PMID: 10880169]
39. Ji W, St CW. Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J Viral Hepat 1997; 4: 167-173 [PMID:9181525 DOI: 10.1046/j.1365-2893.1997.00144.x]
40. Tung FY, Bowen SW. Targeted inhibition of hepatitis B virus gene expression: a gene therapy approach. Front Biosci 1998; 3: a11-a15 [PMID: 9450988]
41. Brantl S. Antisense-RNA regulation and RNA interference. Biochim Biophys Acta 2002; 1575: 15-25 [PMID: 12020814 DOI: 10.1016/S0167-4781(02)00280-4]
42. Hafkemeyer P, Brinkmann U, Brinkmann E, Pastan I, Blum HE, Baumert TF. Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells. World J Gastroenterol 2008; 14: 2810-2817 [PMID: 18473403 DOI: 10.3748/wjg.14.2810]
43. Schubert S, Kurreck J. Ribozyme-and deoxyribozyme-strategies for medical applications. Curr Drug Targets 2004; 5: 667-681 [PMID: 15578948 DOI: 10.2174/1389450043345092]
44. von Weizsäcker F, Blum HE, Wands JR. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992; 189: 743-748 [PMID: 1472046 DOI: 10.1016/0006-291X(92)92264-X]
45. Beck J, Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res 1995; 23: 4954-4962 [PMID: 8559651 DOI: 10.1093/nar/23.24.4954]
46. Welch PJ, Tritz R, Yei S, Barber J, Yu M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 1997; 4: 736-743 [PMID: 9282175 DOI: 10.1038/sj.gt.3300441]
47. Zheng WC, Qi GR. tRNA-embedded Hammerhead Ribozymes Mediate Destruction of HBV (Subtype adr) in vitro. Shengwuhuaxue Yu Shengwuwuli Xuebao (Shanghai) 1998; 30: 432-438 [PMID: 12168009]
48. Bergeron LJ, Perreault JP. Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus. Nucleic Acids Res 2002; 30: 4682-4691 [PMID:12409459 DOI: 10.1093/nar/gkf598]
49. Tan TM, Zhou L, Houssais S, Seet BL, Jaenicke S, Peter F, Lim SG. Intracellular inhibition of hepatitis B virus S gene expression by chimeric DNA-RNA phosphorothioate minimized ribozyme. Antisense Nucleic Acid Drug Dev 2002; 12: 257-264 [PMID:12238814 DOI: 10.1089/108729002320351575]
50. Hoeprich S, Zhou Q, Guo S, Shu D, Qi G, Wang Y, Guo P. Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene Ther 2003; 10: 1258-1267 [PMID:12858191 DOI: 10.1038/sj.gt.3302002]
51. Goila R, Banerjea AC. Sequence-specific cleavage of hepatitis X RNA in cis and trans by novel monotarget and multitarget hammerhead motif-containing ribozymes. Oligonucleotides 2004; 14: 249-262 [PMID: 15665593 DOI: 10.1089/oli.2004.14.249]
52. Ruiz J, Wu CH, Ito Y, Wu GY. Design and preparation of a multimeric self-cleaving hammerhead ribozyme. Biotechniques 1997; 22: 338-345 [PMID: 9043708]
53. Zu Putlitz J, Yu Q, Burke JM, Wands JR. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J Virol 1999; 73: 5381-5387 [PMID: 10364285]
54. Passman M, Weinberg M, Kew M, Arbuthnot P. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun 2000; 268: 728-733 [PMID: 10679273 DOI: 10.1006/bbrc.2000.2209]
55. Zheng WC, Lu CD, Kong YY, Wang Y, Qi GR. Hammerhead Ribozymes Suppress HBV(adr) in HepG2 Cells. Shengwuhuaxue Yu Shengwuwuli Xuebao (Shanghai) 2001; 33: 25-29 [PMID: 12053184]
56. Pan WH, Xin P, Morrey JD, Clawson GA. A self-processing ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and hepatitis B virus. Mol Ther 2004; 9: 596-606 [PMID:15093190 DOI: 10.1016/j.ymthe.2003.12.013]
57. Li X, Kuang E, Dai W, Zhou B, Yang F. Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis delta virus. Virus Res 2005; 114: 126-132 [PMID:16054262 DOI: 10.1016/j.virusres.2005.06.005]
58. Nash KL, Alexander GJ, Lever AM. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. J Viral Hepat 2005; 12: 346-356 [PMID: 15985004 DOI: 10.1111/j.1365-2893.2005.00612.x]
59. Wang CX, Lu YQ, Qi P, Chen LH, Han JX. Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus. Virol J 2010; 7: 61 [PMID:20236514 DOI: 10.1186/1743-422X-7-61]
60. Asahina Y, Ito Y, Wu CH, Wu GY. DNA ribonucleases that are active against intracellular hepatitis B viral RNA targets. Hepatology 1998; 28: 547-554 [PMID: 9696023 DOI: 10.1002/hep.510280236]
61. Goila R, Banerjea AC. Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochem J 2001; 353: 701-708 [PMID: 11171068 DOI: 10.1042/0264-6021: 3530701]
62. Hou W, Wo JE, Li MW, Liu KZ. In vitro cleavage of hepatitis B virus C mRNA by 10-23 DNA enzyme. Hepatobiliary Pancreat Dis Int 2005; 4: 573-576 [PMID: 16286265]
63. Wo JE, Wu XL, Zhou LF, Yao HP, Chen LW, Dennin RH. Effective inhibition of expression of hepatitis B virus genes by DNAzymes. World J Gastroenterol 2005; 11: 3504-3507 [PMID: 15962363]
64. Hou W, Ni Q, Wo J, Li M, Liu K, Chen L, Hu Z, Liu R, Hu M. Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes. Antiviral Res 2006; 72: 190-196 [PMID: 16930733 DOI: 10.1016/j.antiviral.2006.07.001]
65. Scaglioni PP, Melegari M, Wands JR. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 1994; 205: 112-120 [PMID: 7975206 DOI: 10.1006/viro.1994.1625]
66. Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24: 1010-1017 [PMID:8903368 DOI: 10.1002/hep.510240506]
67. von Weizsäcker F, Wieland S, Köck J, Offensperger WB, Offensperger S, Moradpour D, Blum HE. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26: 251-255 [PMID: 9252130 DOI: 10.1002/hep.510260237]
68. von Weizsäcker F, Köck J, Wieland S, Offensperger WB, Blum HE. Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. Hepatology 1999; 30: 308-315 [PMID: 10385672 DOI: 10.1002/hep.510300139]
69. Beterams G, Nassal M. Significant interference with hepatitis B virus replication by a core-nuclease fusion protein. J Biol Chem 2001; 276: 8875-8883 [PMID: 11124940 DOI: 10.1074/jbc. M006335200]
70. Liu J, Li YH, Xue CF, Ding J, Gong WD, Zhao Y, Huang YX. Targeted ribonuclease can inhibit replication of hepatitis B virus. World J Gastroenterol 2003; 9: 295-299 [PMID: 12532452]
71. Liu J, Li YH, Ding J, Gong WD, Xue CF, Zhao Y, Huang YX. Quantifying anti-HBV effect of targeted ribonuclease by realtime fluorescent PCR. World J Gastroenterol 2004; 10: 2883-2885 [PMID: 15334692]
72. Zhao Y, Li Y, Liu J, Liu Z, Huang Y, Lei J, Li S, Xue C. Adenoviral-vector mediated transfer of HBV-targeted ribonuclease can inhibit HBV replication in vivo. Biochem Biophys Res Commun 2008; 371: 541-545 [PMID: 18455508 DOI: 10.1016/j.bbrc.2008.04.121]
73. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Brechot C. [Efficacy of immunotherapy with vaccination against hepatitis B virus on virus B multiplication]. C R Acad Sci III 1993; 316: 688-691 [PMID: 8019891]
74. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother 1995; 49: 105-109 [PMID: 7647280 DOI: 10.1016/0753-3322(96)82602-3]
75. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993; 2: 1847-1851 [PMID: 8281146 DOI: 10.1093/hmg/2.11.1847]
76. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996; 93: 12496-12501 [PMID: 8901610 DOI: 10.1073/pnas.93.22.12496]
77. Townsend K, Sällberg M, O'Dea J, Banks T, Driver D, Sauter S, Chang SM, Jolly DJ, Mento SJ, Milich DR, Lee WT. Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens. J Virol 1997; 71: 3365-3374 [PMID: 9094605]
78. Sällberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K, Anderson CG, O'Dea J, Alfonso J, Eason R, Murthy KK, Jolly DJ, Chang SM, Mento SJ, Milich D, Lee WT. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998; 9: 1719-1729 [PMID:9721082 DOI: 10.1089/hum.1998.9.12-1719]
79. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999; 17: 2826-2829 [PMID: 10438052 DOI: 10.1016/S0264-410X(99)00094-8]
80. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, Vessey R, King A, Ogg G, Gallimore A, Haynes JR, Heydenburg Fuller D. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19: 764-778 [PMID:11115698 DOI: 10.1016/S0264-410X(00)00302-9]
81. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Bréchot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40: 874-882 [PMID: 15382173 DOI: 10.1002/hep.20408]
82. Mancini-Bourgine M, Fontaine H, Bréchot C, Pol S, Michel ML. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006; 24: 4482-4489 [PMID:16310901 DOI: 10.1016/j.vaccine.2005.08.013]
83. Yang FQ, Yu YY, Wang GQ, Chen J, Li JH, Li YQ, Rao GR, Mo GY, Luo XR, Chen GM. A pilot randomized controlled trial of dualplasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 2012; 19: 581-593 [PMID: 22762143 DOI: 10.1111/j.1365-2893.2012.01589.x]
84. Forster AC, Altman S. External guide sequences for an RNA enzyme. Science 1990; 249: 783-786 [PMID: 1697102 DOI: 10.1126/science.1697102]
85. Yuan Y, Hwang ES, Altman S. Targeted cleavage of mRNA by human RNase P. Proc Natl Acad Sci USA 1992; 89: 8006-8010 [PMID: 1381505 DOI: 10.1073/pnas.89.17.8006]
86. Werner M, Rosa E, George ST. Design of short external guide sequences (EGSs) for cleavage of target molecules with RNase P. Nucleic Acids Symp Ser 1997; (36): 19-21 [PMID: 9478194]
87. Werner M, Rosa E, Nordstrom JL, Goldberg AR, George ST. Short oligonucleotides as external guide sequences for site-specific cleavage of RNA molecules with human RNase P. RNA 1998; 4: 847-855 [PMID: 9671057 DOI: 10.1017/S1355838298980323]
88. Werner M, Rosa E, Al Emran O, Goldberg AR, George ST. Targeted cleavage of RNA molecules by human RNase P using minimized external guide sequences. Antisense Nucleic Acid Drug Dev 1999; 9: 81-88 [PMID: 10192292 DOI: 10.1089/oli.1.1999.9.81]
89. Xia C, Chen YC, Gong H, Zeng W, Vu GP, Trang P, Lu S, Wu J, Liu F. Inhibition of hepatitis B virus gene expression and replication by ribonuclease P. Mol Ther 2013; 21: 995-1003 [PMID: 23481322 DOI: 10.1038/mt.2013.37]
90. Zhang Z, Vu GP, Gong H, Xia C, Chen YC, Liu F, Wu J, Lu S. Engineered external guide sequences are highly effective in inhibiting gene expression and replication of hepatitis B virus in cultured cells. PLoS One 2013; 8: e65268 [PMID: 23776459 DOI: 10.1371/journal.pone.0065268]
91. Hannon GJ. RNA interference. Nature 2002; 418: 244-251 [PMID:12110901 DOI: 10.1038/418244a]
92. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811 [PMID:9486653 DOI: 10.1038/35888]
93. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003; 37: 764-770 [PMID: 12668968 DOI: 10.1053/jhep.2003.50146]
94. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-644 [PMID: 12740585 DOI: 10.1038/nbt824]
95. Klein C, Bock CT, Wedemeyer H, Wüstefeld T, Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125: 9-18 [PMID: 12851866 DOI: 10.1016/S0016-5085(03)00720-0]
96. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8: 769-776 [PMID: 14599810 DOI: 10.1016/S1525-0016(03)00244-2]
97. Hamasaki K, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K. Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett 2003; 543: 51-54 [PMID: 12753904 DOI: 10.1016/s0014-5793(03)00400-9]
98. Moore MD, McGarvey MJ, Russell RA, Cullen BR, McClure MO. Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med 2005; 7: 918-925 [PMID: 15756649 DOI: 10.1002/jgm.739]
99. Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 2005; 102: 773-778 [PMID:15640346 DOI: 10.1073/pnas.0409028102]
100. Jia F, Zhang YZ, Liu CM. A retrovirus-based system to stably silence hepatitis B virus genes by RNA interference. Biotechnol Lett 2006; 28: 1679-1685 [PMID: 16900331 DOI: 10.1007/s10529-006-9138-z]
101. Jia F, Zhang YZ, Liu CM. Stable inhibition of hepatitis B virus expression and replication in HepG2.2.15 cells by RNA interference based on retrovirus delivery. J Biotechnol 2007; 128: 32-40 [PMID:17049658 DOI: 10.1016/j.jbiotec.2006.09.007]
102. Chen CC, Ko TM, Ma HI, Wu HL, Xiao X, Li J, Chang CM, Wu PY, Chen CH, Han JM, Yu CP, Jeng KS, Hu CP, Tao MH. Longterm inhibition of hepatitis B virus in transgenic mice by doublestranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007; 14: 11-19 [PMID: 16929350 DOI: 10.1038/sj.gt.3302846]
103. Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008; 16: 1630-1636 [PMID: 18665161 DOI: 10.1038/mt.2008.144]
104. Chen CC, Sun CP, Ma HI, Fang CC, Wu PY, Xiao X, Tao MH. Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther 2009; 17: 352-359 [PMID: 19066602 DOI: 10.1038/mt.2008.245]
105. Sun Y, Li Z, Li L, Li J, Liu X, Li W. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors. Int J Mol Med 2007; 19: 705-711 [PMID: 17334648]
106. Rauschhuber C, Xu H, Salazar FH, Marion PL, Ehrhardt A. Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice. J Gene Med 2008; 10: 878-889 [PMID: 18470951 DOI: 10.1002/jgm.1207]
107. Crowther C, Mowa MB, Ely A, Arbuthnot PB. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther 2014; 19: 363-373 [PMID: 24296696 DOI: 10.3851/imp2713]
108. Deng L, Li G, Xi L, Yin A, Gao Y, You W, Wang X, Sun B. Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. BMC Gastroenterol 2009; 9: 73 [PMID:19804649 DOI: 10.1186/1471-230X-9-73]
109. Xiangji L, Feng X, Qingbao C, Weifeng T, Xiaoqing J, Baihe Z, Feng S, Hongyang W, Mengchao W. Knockdown of HBV surface antigen gene expression by a lentiviral microRNA-based system inhibits HBV replication and HCC growth. J Viral Hepat 2011; 18: 653-660 [PMID: 20642484 DOI: 10.1111/j.1365-2893.2010.01346. x]
110. Starkey JL, Chiari EF, Isom HC. Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. J Gen Virol 2009; 90: 115-126 [PMID: 19088280 DOI: 10.1099/vir.0.004408-0]
111. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007 [PMID: 16041363 DOI: 10.1038/nbt1122]
112. Peng J, Zhao Y, Mai J, Pang WK, Wei X, Zhang P, Xu Y. Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties. J Gen Virol 2005; 86: 3227-3234 [PMID: 16298967 DOI: 10.1099/vir.0.81171-0]
113. Wu K, Gong Y, Zhang X, Zhang Y, Mu Y, Liu F, Song D, Zhu Y, Wu J. Inhibition of hepatitis B virus replication by recombinant small interfering RNAs. Acta Virol 2005; 49: 235-241 [PMID: 16402680]
114. Wu KL, Zhang X, Zhang J, Yang Y, Mu YX, Liu M, Lu L, Li Y, Zhu Y, Wu J. Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. Virus Res 2005; 112: 100-107 [PMID: 16022904 DOI: 10.1016/j.virusres.2005.04.001]
115. Weinberg MS, Ely A, Barichievy S, Crowther C, Mufamadi S, Carmona S, Arbuthnot P. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther 2007; 15: 534-541 [PMID: 17213835 DOI: 10.1038/sj.mt.6300077]
116. Ely A, Naidoo T, Arbuthnot P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res 2009; 37: e91 [PMID:19474340 DOI: 10.1093/nar/gkp446]
117. Gish RG, Satishchandran C, Young M, Pachuk C. RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. Antivir Ther 2011; 16: 547-554 [PMID: 21685542 DOI: 10.3851/IMP1798]
118. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541 [PMID: 16724069 DOI: 10.1038/nature04791]
119. Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther 2008; 16: 1105-1112 [PMID: 18431360 DOI: 10.1038/mt.2008.82]
120. Jenke AC, Wilhelm AD, Orth V, Lipps HJ, Protzer U, Wirth S. Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1. Antimicrob Agents Chemother 2008; 52: 2355-2359 [PMID: 18474581 DOI: 10.1128/aac.00067-08]
121. Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, Hegge JO, Klein JJ, Wakefield DH, Oropeza CE, Deckert J, Roehl I, Jahn-Hofmann K, Hadwiger P, Vornlocher HP, McLachlan A, Lewis DL. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013; 21: 973-985 [PMID: 23439496 DOI: 10.1038/mt.2013.31]
122. Li Z. Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520. 2014. Available from: URL: http://www.arrowheadresearch.com/press-releases/arrowhead-completes-enrollment-first-cohort-phase-2a-trialchronic-hepatitis-b-0
123. Chinnappan M, Singh AK, Kakumani PK, Kumar G, Rooge SB, Kumari A, Varshney A, Rastogi A, Singh AK, Sarin SK, Malhotra P, Mukherjee SK, Bhatnagar RK. Key elements of the RNAi pathway are regulated by hepatitis B virus replication and HBx acts as a viral suppressor of RNA silencing. Biochem J 2014; 462: 347-358 [PMID:24902849 DOI: 10.1042/BJ20140316]
124. Bibikova M, Carroll D, Segal DJ, Trautman JK, Smith J, Kim YG, Chandrasegaran S. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol 2001; 21: 289-297 [PMID: 11113203 DOI: 10.1128/MCB.21.1.289-297.2001]
125. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD, Holmes MC, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-1306 [PMID: 17965707 DOI: 10.1038/nbt1353]
126. Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, Katibah GE, Amora R, Boydston EA, Zeitler B, Meng X, Miller JC, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Jaenisch R. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009; 27: 851-857 [PMID: 19680244 DOI: 10.1038/nbt.1562]
127. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011; 39: e82 [PMID: 21493687 DOI: 10.1093/nar/gkr218]
128. Li T, Huang S, Zhao X, Wright DA, Carpenter S, Spalding MH, Weeks DP, Yang B. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res 2011; 39: 6315-6325 [PMID:21459844 DOI: 10.1093/nar/gkr188]
129. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821 [PMID:22745249 DOI: 10.1126/science.1225829]
130. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-823 [PMID:23287718 DOI: 10.1126/science.1231143]
131. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science 2013; 339: 823-826 [PMID: 23287722 DOI: 10.1126/science.1232033]
132. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 2012; 47: 497-510 [PMID: 22920291 DOI: 10.1016/j.molcel.2012.07.029]
133. Blancafort P, Segal DJ, Barbas CF. Designing transcription factor architectures for drug discovery. Mol Pharmacol 2004; 66: 1361-1371 [PMID: 15340042 DOI: 10.1124/mol.104.002758]
134. Cathomen T, Joung JK. Zinc-finger nucleases: the next generation emerges. Mol Ther 2008; 16: 1200-1207 [PMID: 18545224 DOI: 10.1038/mt.2008.114]
135. Carroll D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther 2008; 15: 1463-1468 [PMID: 18784746 DOI: 10.1038/gt.2008.145]
136. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 1996; 93: 1156-1160 [PMID: 8577732 DOI: 10.1073/pnas.93.3.1156]
137. Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 2008; 82: 8013-8021 [PMID: 18524822 DOI: 10.1128/JVI.00366-08]
138. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010; 18: 947-954 [PMID:20160705 DOI: 10.1038/mt.2010.20]
139. Weber ND, Stone D, Sedlak RH, De Silva Feelixge HS, Roychoudhury P, Schiffer JT, Aubert M, Jerome KR. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One 2014; 9: e97579 [PMID: 24827459 DOI: 10.1371/journal.pone.0097579]
140. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8: 1248-1254 [PMID: 11509958 DOI: 10.1038/sj.gt.3301514]
141. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, Lahaye T, Nickstadt A, Bonas U. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009; 326: 1509-1512 [PMID: 19933107 DOI: 10.1126/science.1178811]
142. Neff KL, Argue DP, Ma AC, Lee HB, Clark KJ, Ekker SC. Mojo Hand, a TALEN design tool for genome editing applications. BMC Bioinformatics 2013; 14: 1 [PMID: 23323762 DOI: 10.1186/1471-2105-14-1]
143. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012; 30: 460-465 [PMID: 22484455 DOI: 10.1038/nbt.2170]
144. Schmid-Burgk JL, Schmidt T, Kaiser V, Höning K, Hornung V. A ligation-independent cloning technique for high-throughput assembly of transcription activator-like effector genes. Nat Biotechnol 2013; 31: 76-81 [PMID: 23242165 DOI: 10.1038/nbt.2460]
145. Uhde-Stone C, Gor N, Chin T, Huang J, Lu B. A do-it-yourself protocol for simple transcription activator-like effector assembly. Biol Proced Online 2013; 15: 3 [PMID: 23316790 DOI: 10.1186/1480-9222-15-3]
146. Bloom K, Ely A, Mussolino C, Cathomen T, Arbuthnot P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 2013; 21: 1889-1897 [PMID: 23883864 DOI: 10.1038/mt.2013.170]
147. Chen J, Zhang W, Lin J, Wang F, Wu M, Chen C, Zheng Y, Peng X, Li J, Yuan Z. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther 2014; 22: 303-311 [PMID: 24025750 DOI: 10.1038/mt.2013.212]
148. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, Chen PJ. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids 2014; 3: e186 [PMID: 25137139 DOI: 10.1038/mtna.2014.38]